tp53(ashish)

Hi, I’m Ashish

I go by tp53 online, named after the tumor suppressor gene that’s central to cancer research. To learn more about tp53, I highly recommend this very accessible (even to laymen!) substack post by Stetson Thacker on tp53, the tumor suppressor to rule them all, often also christened “the guardian of the genome”.

I’m an engineer passionate about accelerating drug discovery and building tools at the intersection of machine learning and medicine. My focus is on cancer and oncology - from genomics and protein design to clinical trials and treatment planning.

What I’m working on

My mission is to impact medicine and disease through technology:

Building tools for drug discovery - Developing systems to accelerate the discovery of new therapeutics, especially for cancers where good treatments don’t exist today.

Building tools for healthcare - Using AI and biomedical data to help clinicians make better decisions faster, and to help patients become more engaged in their care.

See my projects for details on computational protein design, bio ML challenges, and regulatory analysis work.

New
Analysis

DADB-v1.0 Benchmark

A Therapeutic Decathlon for De Novo Antibody Design

The first comprehensive benchmark measuring what actually matters: binding, structure, developability, and immunogenicity. Featuring 5 AI platforms with first-ever human immunogenicity data.

🆕 Available Online: 29 January 2026

Read Proposal →
Featured
AI + Healthcare

Virtual Tumor Board

7 AI Specialists. 256 Guidelines. One Consensus.

Multi-agent AI that simulates a real tumor board meeting. Surgical, medical, radiation oncology, palliative care, radiology, pathology, and genetics specialists deliberate on cancer cases—grounded in NCCN, ESMO, ASTRO guidelines with Indian healthcare context.

Try Live Demo →
Analysis

Antibodies from Thin Air

Four AI Platforms Rewriting Cancer Drug Discovery

A comparison of JAM-2, Chai-2, Origin-1, and RFAntibody—de novo antibody design platforms achieving 15-40% hit rates and sub-nanomolar GPCR binders. Includes oncology target analysis and a primer on antibody biology.

Read Analysis →
New

Onco-Seg

Adapting SAM3 for Medical Image Segmentation

Multi-modal AI for tumor & organ segmentation across CT, MRI, ultrasound, and 5 more modalities. Trained on 98K+ cases using parameter-efficient LoRA fine-tuning.

View Project →
Onco-Seg demo

Background

I trained as an engineer during undergrad and got my Master’s in Computer Engineering at Purdue. Over the past several years, personal experiences and encounters with patients and doctors have inspired me to pursue a career at the intersection of tech and medicine.

Check out my curated reading list on cancer research, drug discovery, and rare diseases.


When I’m not working, I enjoy long walks, chai, cycling, standup comedy, and spending time with family.